Breast Cancer Monoclonal Antibodies Market Projected at $27.8 Billion by 2029 | Strategic Insights and Forecast Data
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has The Breast Cancer Monoclonal Antibodies Market Size Shifted, And What Is the Outlook Through 2034?
The market size of breast cancer monoclonal antibodies has experienced a significant expansion in the recent past. The market, which stood at $18.97 billion in 2024, is expected to reach $20.18 billion in 2025, growing at a compound annual growth rate (CAGR) of 6.4%. This growth during the historical period has been driven by factors such as the increasing occurrence of breast cancer, heightened awareness regarding breast cancer monoclonal antibodies, enhanced clinical effectiveness, and rising patient demand.
How Much Will the Breast Cancer Monoclonal Antibodies Market Be Worth in 2029?
In the coming years, the breast cancer monoclonal antibodies market is projected to witness substantial growth, escalating to a size of $27.8 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this surge during the forecast period include the rise of emerging targets, biosimilars, combination treatments, increased global incidence, an aging population, and the growth of personalized medicine. Key trends likely to be observed during this period incorporate advancements in early detection of breast cancer, the incorporation of immunotherapy, liquid biopsies, companion diagnostics, adjuvant and neoadjuvant therapies, as well as improved support for long-term survivors.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3450&type=smp
Which is the Largest Company in the Breast Cancer Monoclonal Antibodies Market?
Major companies operating in the breast cancer monoclonal antibodies market include Amgen Inc., Mylan N.V., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc., Daiichi Sankyo Company Ltd., Biocad, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celldex Therapeutics Inc., Celltrion Inc., F. Hoffmann-La Roche AG, Immunomedics Inc., MacroGenics Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Puma Biotechnology Inc., Seattle Genetics Inc., AstraZeneca plc, Eddingpharm, Eisai Co. Ltd., ImmunoGen Inc., Eli Lilly and Company, AbbVie Inc., Johnson & Johnson, Mersana Therapeutics Inc., Immunocore Limited, Immunovative Therapies Ltd.
What Are the Main Market Drivers in the Breast Cancer Monoclonal Antibodies Industry?
The surge in breast cancer occurrences is forecasted to fuel the expansion of the breast cancer monoclonal antibody market. For example, the American Cancer Society, a nonprofit organization dedicated to cancer advocacy in the US, reported in January 2023 that the number of breast cancer incidences escalated from 284,200 in 2021 to 300,590 in 2023, exhibiting a 5.76% increase. Consequently, this escalating worldwide breast cancer prevalence is anticipated to stimulate the growth of the breast cancer monoclonal antibody market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=3450&type=smp
How Is the Breast Cancer Monoclonal Antibodies Market Segments Structured?
The breast cancer monoclonal antibodies market covered in this report is segmented –
1) By Product: Naked Mabs, Conjugated Mabs
2) By Treatment: Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy
3) By End-User: Hospitals, Retail Pharmacies
Subsegments:
1) By Naked MABs: Trastuzumab (Herceptin), Rituximab, Cetuximab, Other Naked MABs
2) By Conjugated MABs: Ado-trastuzumab emtansine (Kadcyla), Brentuximab vedotin, Other Conjugated MABs
What Strategic Trends Are Transforming the Breast Cancer Monoclonal Antibodies Market?
The rising global trend towards alternative therapies and natural remedies is anticipated to influence the revenue of companies manufacturing breast cancer monoclonal antibodies. There is an increasing reliance on modalities like homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy, which are slowly substituting conventional hospital procedures. For example, the age-old Indian medicinal system, Ayurveda, employs various procedures and remedies for cancer treatment, with several Ayurvedic herbs possessing anti-cancer properties. The World Health Organization (WHO) reports that plant-based treatments are still the primary source of medicine for some countries, while developing nations harness the therapeutic benefits of natural compounds, which impacts the sales of cancer drugs. Furthermore, the worldwide market for homeopathic products is predicted to hit $18.6 billion by 2027. The National Cancer Institute has alluded to the encouraging results of vaccines in HER2-positive cancers like breast, ovarian, lung, colorectal, and gastroesophageal, where the patient’s immune cells are genetically altered to develop personalized vaccines. These elements are likely to persist over the forecasted period, thereby curbing the demand for the breast cancer monoclonal antibodies market.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Breast Cancer Monoclonal Antibodies Market?
The countries covered in the breast cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3450
This Report Delivers Insight On:
1. How big is the breast cancer monoclonal antibodies market, and how is it changing globally?
2. Who are the major companies in the breast cancer monoclonal antibodies market, and how are they performing?
3. What are the key opportunities and risks in the breast cancer monoclonal antibodies market right now?
4. Which products or customer segments are growing the most in the breast cancer monoclonal antibodies market?
5. What factors are helping or slowing down the growth of the breast cancer monoclonal antibodies market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
